| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 53.8 |
| Profit before tax | -68.4 | 15.9 |
| Net income | -68.4 | 15.9 |
| EPS (diluted, $ a share) | $-0.39 | $0.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TNGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tango Therapeutics, Inc.: key numbers
- Share price
- $24.17Close, Nov 16
- Market cap
- $4.1B
- Shares outstanding
- 169.46MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tango Therapeutics, Inc.
All →Tango Therapeutics President, R&D Adam Crystal Sells $125K of Stock
Adam Crystal, President, R&D, sold 5,000 shares of Tango Therapeutics, Inc. at $25.00 a share, worth $125K in total on Nov 11, 2026. Shares held after the trade: 115,743 (-4.1%).
- Value
- $125K
- Shares
- 5,000
- Price
- $25.00
- Role
- President, R&D
- Holding change
- -4.1%
- Trade date
- Nov 11, 2026
Tango Therapeutics Financial Results
Tango Therapeutics reported third quarter 2026 financial results, highlighting a strong cash position of $977.5 million. The company announced plans to initiate a pivotal Phase 3 study of vopimetostat plus daraxonrasib for front-line pancreatic cancer in the first half of 2027 following positive Phase 1/2 data.
“In 2026, Tango has made significant strides towards bringing vopimetostat to patients with pancreatic cancer. This progress is rooted first in the data. Last month at ESMO, we shared promising data from the combination of vopimetostat plus daraxonrasib that reinforced the potential of this program to raise the bar for patients with MTAP-deleted and RAS-mutant pancreatic cancer.”
Malte Peters, MD, President and Chief Executive Officer of Tango
Tango Therapeutics President, R&D Adam Crystal Sells $112K of Stock
Adam Crystal, President, R&D, sold 5,000 shares of Tango Therapeutics, Inc. at $22.26 to $22.99 a share (average $22.42) in 2 transactions, worth $112K in total on Nov 2, 2026. Shares held after the trade: 115,743 (-0.9%).
- Value
- $112K
- Shares
- 5,000
- Average price
- $22.42
- Role
- President, R&D
- Holding change
- -0.9%
- Trade date
- Nov 2, 2026
Tango Therapeutics Principal Accounting Officer Jessica Newcomb Sells $158K of Stock
Jessica Newcomb, Principal Accounting Officer, sold 7,031 shares of Tango Therapeutics, Inc. at $22.28 to $22.98 a share (average $22.42) in 2 transactions, worth $158K in total on Nov 2, 2026. Shares held after the trade: 52,090 (-2.7%).
- Value
- $158K
- Shares
- 7,031
- Average price
- $22.42
- Role
- Principal Accounting Officer
- Holding change
- -2.7%
- Trade date
- Nov 2, 2026
Tango Therapeutics Clinical Trial Data
Tango Therapeutics announced updated Phase 1/2 clinical trial results for vopimetostat in combination with daraxonrasib, showing an 82% objective response rate in patients with MTAP-deleted and RAS-mutant pancreatic cancer. The data demonstrated a 9-month progression-free survival rate of 88%, leading the company to plan a registrational Phase 3 trial in the first half of 2027.
- Counterparty
- Revolution Medicines, Inc.
Tango Therapeutics President, R&D Adam Crystal Sells $661K of Stock
Adam Crystal, President, R&D, sold 27,000 shares of Tango Therapeutics, Inc. at $24.45 to $25.32 a share (average $24.47) in 2 transactions, worth $661K in total on Oct 1, 2026. Shares held after the trade: 115,743 (-0.5%).
- Value
- $661K
- Shares
- 27,000
- Average price
- $24.47
- Role
- President, R&D
- Holding change
- -0.5%
- Trade date
- Oct 1, 2026